Zobrazeno 1 - 10
of 218
pro vyhledávání: '"Olivier Rixe"'
Autor:
Jason J. Luke, Jedd D. Wolchok, Taha Merghoub, Cynthia A. Sirard, Diane Piper, Lianna Sifferlen, Phillip Wong, Aliya Holland, Jingjing Qi, Walter Newman, Olivier Rixe, David Bajor, Todd Bauer, Takami Sato, Girish S. Naik, Hong Wang, Roberta Zappasodi, Diwakar Davar
Supplementary Table from Phase IB Study of GITR Agonist Antibody TRX518 Singly and in Combination with Gemcitabine, Pembrolizumab, or Nivolumab in Patients with Advanced Solid Tumors
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::06e8274a662db94b0372cb7e7542e809
https://doi.org/10.1158/1078-0432.22486856
https://doi.org/10.1158/1078-0432.22486856
Autor:
Jason J. Luke, Jedd D. Wolchok, Taha Merghoub, Cynthia A. Sirard, Diane Piper, Lianna Sifferlen, Phillip Wong, Aliya Holland, Jingjing Qi, Walter Newman, Olivier Rixe, David Bajor, Todd Bauer, Takami Sato, Girish S. Naik, Hong Wang, Roberta Zappasodi, Diwakar Davar
Purpose:TRX518 is a mAb engaging the glucocorticoid-induced TNF receptor−related protein (GITR). This open-label, phase I study (TRX518-003) evaluated the safety and efficacy of repeated dose TRX518 monotherapy and in combination with gemcitabine,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d505d5d9e72ee2c945357f5aef741ec3
https://doi.org/10.1158/1078-0432.c.6532406.v1
https://doi.org/10.1158/1078-0432.c.6532406.v1
Autor:
Jason J. Luke, Jedd D. Wolchok, Taha Merghoub, Cynthia A. Sirard, Diane Piper, Lianna Sifferlen, Phillip Wong, Aliya Holland, Jingjing Qi, Walter Newman, Olivier Rixe, David Bajor, Todd Bauer, Takami Sato, Girish S. Naik, Hong Wang, Roberta Zappasodi, Diwakar Davar
Supplementary Data from Phase IB Study of GITR Agonist Antibody TRX518 Singly and in Combination with Gemcitabine, Pembrolizumab, or Nivolumab in Patients with Advanced Solid Tumors
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1b804d37d72c5b64ee02158bbc8605da
https://doi.org/10.1158/1078-0432.22486880
https://doi.org/10.1158/1078-0432.22486880
Autor:
Jason J. Luke, Jedd D. Wolchok, Taha Merghoub, Cynthia A. Sirard, Diane Piper, Lianna Sifferlen, Phillip Wong, Aliya Holland, Jingjing Qi, Walter Newman, Olivier Rixe, David Bajor, Todd Bauer, Takami Sato, Girish S. Naik, Hong Wang, Roberta Zappasodi, Diwakar Davar
Supplementary Figure from Phase IB Study of GITR Agonist Antibody TRX518 Singly and in Combination with Gemcitabine, Pembrolizumab, or Nivolumab in Patients with Advanced Solid Tumors
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3addefab290e824d920fb0999caa57c8
https://doi.org/10.1158/1078-0432.22486877
https://doi.org/10.1158/1078-0432.22486877
Autor:
Diwakar Davar, Roberta Zappasodi, Hong Wang, Girish S. Naik, Takami Sato, Todd Bauer, David Bajor, Olivier Rixe, Walter Newman, Jingjing Qi, Aliya Holland, Phillip Wong, Lianna Sifferlen, Diane Piper, Cynthia A. Sirard, Taha Merghoub, Jedd D. Wolchok, Jason J. Luke
Publikováno v:
Clin Cancer Res
Purpose: TRX518 is a mAb engaging the glucocorticoid-induced TNF receptor−related protein (GITR). This open-label, phase I study (TRX518-003) evaluated the safety and efficacy of repeated dose TRX518 monotherapy and in combination with gemcitabine,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::60473b0d4d51a50755b6880e00e30770
https://europepmc.org/articles/PMC9475244/
https://europepmc.org/articles/PMC9475244/
Autor:
Robert Wesolowski, Anne M. Noonan, Richard Charles Curry, John Charles Morris, Carolyn Muller, Vinay K. Puduvalli, Olivier Rixe, John L. Villano, Trisha Michel Wise-Draper, Emrullah Yilmaz, Gilles Tapolsky, Ray Takigiku
Publikováno v:
Journal of Clinical Oncology. 41:93-93
93 Background: Chemotherapy Induced Peripheral Neuropathy (CIPN) is a debilitating side effect associated with many chemotherapeutic agents. It significantly impacts quality of life during treatment, causes lasting neuropathy, and may also shorten th
Autor:
Olivier Rixe, Richard Charles Curry, John Charles Morris, Carolyn Muller, Anne M. Noonan, Vinay K. Puduvalli, John L. Villano, Trisha Michel Wise-Draper, Robert Wesolowski, Emrullah Yilmaz, Gilles Tapolsky, Ray Takigiku
Publikováno v:
Journal of Clinical Oncology. 41:154-154
154 Background: Sphingolipids are a class of bioactive signaling molecules implicated in multiple cellular processes and molecular pathways. Many publications have demonstrated that ceramides are proapoptotic, synergize with cancer treatments, and mi
Autor:
Sarah Adams, Carolyn Muller, David O’Malley, Kari Ring, Robert Wenham, Karen Finkelstein, Teresa Rutledge, Elizabeth Lokich, Xavier Paliard, Olivier Rixe, Ichiko Kinjyo, Steven Eberhardt, Ji-Hyun Lee, Phyllis Gimotty
Publikováno v:
Gynecologic Oncology. 166:S60-S61
Autor:
Anthony J. Olszanski, Patrick M. Forde, Olivier Rixe, Yanyan Lou, Asha Nayak-Kapoor, David S. Hong, Vi K. Chiu, Floyd Fox, Margaret A. Marshall, Agron Collaku, Tomislav Dragovich, Rom Leidner, James N. Atkins
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 28(3)
Purpose: The aim of the study was to determine safety, antitumor activity, and pharmacodynamic profile of mogamulizumab, an anti-CCR4 monoclonal antibody targeting effector regulatory T cells (Treg) in combination with the checkpoint inhibitor nivolu
Autor:
Olivier Rixe, Vincent Castonguay, Henry Conter, Eva Chalas, Pratibha Desai, Christian Squillante, Lisa A. MacDonald, Rebekah Conlon, Yogesh Bramhecha, Heather Hirsch, Jeremy R. Graff, Stephan Fiset
Publikováno v:
Cancer Research. 82:CT035-CT035
Background: Maveropepimut-S (MVP-S) is a novel immunotherapeutic that educates a specific CD8 T cell response to the cancer antigen, survivin, to orchestrate immune-mediated elimination of survivin-expressing cancer cells. Specifically, MVP-S is a li